The Itga8-CreERT2 model that we used for specific deletion of Srf in vascular SMCs was developed to circumvent lethal visceral myopathies often seen with deletion strategies that target all SMCs (14). This evidence concerns the gene ITGA8 and familial visceral myopathy.